October 07, 2026 06:54 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘Vote thief’ Gyanesh Kumar: Rahul Gandhi climbs barricade, waves Tricolour during explosive INDIA bloc protest | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘He should not have been flying’: JD Vance on Flydubai co-pilot | Israel was ready to shoot down Flydubai jet if it kept flying towards Tel Aviv: Reports | 'If law wasn't followed, we can undo it': Supreme Court's big warning on SIR process amid Gyanesh Kumar row | From TMC Rajya Sabha MP to BJP nominee in 6 months: Koel Mallick's stunning political U-turn | ‘Stomp on your head’: Omani flydubai co-pilot’s chilling posts on violence against women surface | Asian Games 2026: India beat Pakistan to clinch gold in men's cricket | flydubai cockpit attack: Deleted posts expose Omani co-pilot’s views on women, alleged extremist past
Covaxin

Brazil denies permission to import Bharat Biotech developed Covaxin

| @indiablooms | Apr 01, 2021, at 04:41 am

New Delhi/IBNS:  Brazil's health regulator has denied permission to import Covaxin, the coronavirus vaccine developed by India's indigenous firm Bharat Biotech.

According to reports, a Brazilian government gazette had said that Covaxin had been rejected "considering the non-compliance with the requirements of Good Manufacturing Practices for Medicines''.

In its response to the same, Bharat Biotech has told NDTV: ''The requirements pointed out during inspection will be fulfilled, the timelines for fulfilment is under discussion with the Brazil NRA and will be resolved soon.''

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research.

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

Bharat Biotech said the vaccine is effective against the UK variant of the virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.